Literature DB >> 4014668

New spectrophotometric and radiochemical assays for acetyl-CoA: arylamine N-acetyltransferase applicable to a variety of arylamines.

H H Andres, A J Klem, S M Szabo, W W Weber.   

Abstract

Simple and sensitive spectrophotometric and radiochemical procedures are described for the assay of acetyl-CoA:arylamine N-acetyltransferase (NAT; EC 2.3.1.5), which catalyzes the reaction acetyl-CoA + arylamine----N-acetylated arylamine + CoASH. The methods are applicable to crude tissue homogenates and blood lysates. The spectrophotometric assay is characterized by two features: (i) NAT activity is measured by quantifying the disappearance of the arylamine substrate as reflected by decreasing Schiff's base formation with dimethylaminobenzaldehyde. (ii) During the enzymatic reaction, the inhibitory product CoASH is recycled by the system acetyl phosphate/phosphotransacetylase to the substrate acetyl-CoA. The radiochemical procedure depends on enzymatic synthesis of [3H]acetyl-CoA in the assay using [3H]acetate, ATP, CoASH, and acetyl-CoA synthetase. NAT activity is measured by quantifying N-[3H]acetylarylamine after separation from [3H]acetate by extraction. Product inhibition by CoASH is prevented in this system by the use of acetyl-CoA synthetase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4014668     DOI: 10.1016/0003-2697(85)90376-8

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  6 in total

1.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

2.  Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

Authors:  D M Grant; K Mörike; M Eichelbaum; U A Meyer
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

3.  Kinetic characterisation of arylamine N-acetyltransferase from Pseudomonas aeruginosa.

Authors:  Isaac M Westwood; Edith Sim
Journal:  BMC Biochem       Date:  2007-03-20       Impact factor: 4.059

4.  Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.

Authors:  Nicola Laurieri; Akane Kawamura; Isaac M Westwood; Amy Varney; Elizabeth Morris; Angela J Russell; Lesley A Stanley; Edith Sim
Journal:  BMC Pharmacol Toxicol       Date:  2014-11-29       Impact factor: 2.483

5.  Treatment of Rats with Apocynin Has Considerable Inhibitory Effects on Arylamine N-Acetyltransferase Activity in the Liver.

Authors:  Sheena Francis; Nicola Laurieri; Chukwuemeka Nwokocha; Rupika Delgoda
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

6.  From arylamine N-acetyltransferase to folate-dependent acetyl CoA hydrolase: impact of folic acid on the activity of (HUMAN)NAT1 and its homologue (MOUSE)NAT2.

Authors:  Nicola Laurieri; Julien Dairou; James E Egleton; Lesley A Stanley; Angela J Russell; Jean-Marie Dupret; Edith Sim; Fernando Rodrigues-Lima
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.